Patents by Inventor Bruno Melillo

Bruno Melillo has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20240131032
    Abstract: Disclosed herein are methods, pharmaceutical compositions, and vaccines for modulating an immune response. Also disclosed herein are methods, pharmaceutical compositions, and vaccines for inducing an immune response.
    Type: Application
    Filed: October 15, 2020
    Publication date: April 25, 2024
    Inventors: Benjamin CRAVATT, Ekaterina VINOGRADOVA, Vincent CROWLEY, Xiaoyu ZHANG, Michael Andreas SCHAFROTH, Minoru YOKOYAMA, Dave REMILLARD, Bruno MELILLO, Stuart SCHREIBER
  • Patent number: 11866441
    Abstract: Provided herein are compounds useful for the treatment of various parasitic diseases. These compounds, as well as pharmaceutically acceptable salts thereof may be formulated in pharmaceutical compostions, veterinary compositions and may be used in methods of treatment and/or prophylaxis of diseases spread by parasites, including malaria and cryptosporidiosis.
    Type: Grant
    Filed: July 28, 2021
    Date of Patent: January 9, 2024
    Assignees: THE BROAD INSTITUTE, INC., PRESIDENT AND FELLOWS OF HARVARD COLLEGE
    Inventors: Eamon Comer, Nobutaka Kato, Marshall Morningstar, Bruno Melillo
  • Publication number: 20230279018
    Abstract: The invention provides agents that inhibit L-Phe in cytoplasmic phenylalanine tRNA-synthetase (cFRS), methods for identifying them, compositions comprising such agents, and therapeutic methods of using such agents.
    Type: Application
    Filed: March 22, 2023
    Publication date: September 7, 2023
    Applicants: The Broad Institute, Inc., President and Fellows of Harvard College, Eisai R&D Management Co., LTD.
    Inventors: Eamon COMER, Bruno MELILLO, Francis G. FANG, Branko MITASEV
  • Publication number: 20230009323
    Abstract: Cryptosporidium is a leading contributor to early childhood mortality, and fully effective treatment for this important infectious disease is lacking. A bicyclic azetidine compound series is disclosed having potent in vitro activity against all C. parvum isolates tested, comparable potencies against C. hominis and C. parvum, and cured cryptosporidiosis in highly susceptible immunosuppressed mice with once-daily dosing.
    Type: Application
    Filed: October 23, 2020
    Publication date: January 12, 2023
    Applicants: The Broad Institute, Inc., President and Fellows of Harvard College, The University of Vermont and State Agriculture College
    Inventors: Eamon COMER, Bruno MELILLO, Christopher D. HUSTON
  • Publication number: 20220193034
    Abstract: Provided herein are compounds useful for the treatment of various parasitic diseases. These compounds, as well as pharmaceutically acceptable salts thereof may be formulated in pharmaceutical compositions, veterinary compositions and may be used in methods of treatment and/or prophylaxis of diseases spread by parasites, including cryptosporidiosis.
    Type: Application
    Filed: April 22, 2020
    Publication date: June 23, 2022
    Applicants: WASHINGTON UNIVERSITY, THE BROAD INSTITUTE, INC., PRESIDENT AND FELLOWS OF HARVARD COLLEGE
    Inventors: Laurence David Sibley, Bruno Melillo, Eamon Comer
  • Publication number: 20220162211
    Abstract: Provided herein are compounds useful for the treatment of various parasitic diseases. These compounds, as well as pharmaceutically acceptable salts thereof may be formulated in pharmaceutical compostions, veterinary compositions and may be used in methods of treatment and/or prophylaxis of diseases spread by parasites, including malaria and cryptosporidiosis.
    Type: Application
    Filed: July 28, 2021
    Publication date: May 26, 2022
    Applicants: THE BROAD INSTITUTE, INC., PRESIDENT AND FELLOWS OF HARVARD COLLEGE
    Inventors: EAMON COMER, NOBUTAKA KATO, MARSHALL MORNINGSTAR, BRUNO MELILLO
  • Publication number: 20220033404
    Abstract: Provided herein are compounds useful for the treatment of diseases caused by infections of T. gondii, and closely related parasites. These compounds, as well as pharmaceutically acceptable salts thereof may be formulated in pharmaceutical compositions including veterinary compositions and may be used in methods of treatment and/or prophylaxis of disease.
    Type: Application
    Filed: September 18, 2019
    Publication date: February 3, 2022
    Applicants: WASHINGTON UNIVERSITY, THE BROAD INSTITUTE, INC., PRESIDENT AND FELLOWS OF HARVARD COLLEGE
    Inventors: L. DAVID SIBLEY, JOSHUA RADKE, EAMON COMER, MARSHALL MORNINGSTAR, BRUNO MELILLO
  • Patent number: 11174260
    Abstract: Provided herein are compounds useful for the treatment of various parasitic diseases. These compounds, as well as pharmaceutically acceptable salts thereof may be formulated in pharmaceutical compostions, veterinary compositions and may be used in methods of treatment and/or prophylaxis of diseases spread by parasites, including malaria and cryptosporidiosis.
    Type: Grant
    Filed: March 20, 2018
    Date of Patent: November 16, 2021
    Assignees: THE BROAD INSTITUTE, INC., PRESIDENT AND FELLOWS OF HARVARD COLLEGE
    Inventors: Eamon Comer, Nobutaka Kato, Marshall Morningstar, Bruno Melillo
  • Publication number: 20200095253
    Abstract: Provided herein are compounds useful for the treatment of various parasitic diseases. These compounds, as well as pharmaceutically acceptable salts thereof may be formulated in pharmaceutical compostions, veterinary compositions and may be used in methods of treatment and/or prophylaxis of diseases spread by parasites, including malaria and cryptosporidiosis.
    Type: Application
    Filed: March 20, 2018
    Publication date: March 26, 2020
    Applicants: THE BROAD INSTITUTE, INC., PRESIDENT AND FELLOWS OF HARVARD COLLEGE
    Inventors: EAMON COMER, NOBUTAKA KATO, MARSHALL MORNINGSTAR, BRUNO MELILLO
  • Patent number: 9975848
    Abstract: The disclosure provides compositions and methods for sensitizing primary HIV-1, including transmitted/founder viruses, to neutralization by monoclonal antibodies, e.g., those directed against CD4-induced (CD4i) epitopes and the V3 region. In certain embodiments, the disclosure relates to the use of small molecules as microbicides to inhibit HIV-1 infection directly and to sensitize primary HIV-1 to neutralization by readily elicited antibodies.
    Type: Grant
    Filed: August 13, 2015
    Date of Patent: May 22, 2018
    Assignees: The Trustees of the University of Pennsylvania, Dana-Farber Cancer Institute, Inc., Bryn Mawr College
    Inventors: Amos B. Smith, III, Joseph Sodroski, Navid Madani, Bruno Melillo, Judith M. LaLonde, Amy M. Princiotto
  • Publication number: 20170233335
    Abstract: The disclosure provides compositions and methods for sensitizing primary HIV-1, including transmitted/founder viruses, to neutralization by monoclonal antibodies, e.g., those directed against CD4-induced (CD4i) epitopes and the V3 region. In certain embodiments, the disclosure relates to the use of small molecules as microbicides to inhibit HIV-1 infection directly and to sensitize primary HIV-1 to neutralization by readily elicited antibodies.
    Type: Application
    Filed: August 13, 2015
    Publication date: August 17, 2017
    Inventors: Amos B. SMITH,, III, Joseph SODROSKI, Navid MADANI, Bruno MELILLO, Judith M. LALONDE, Amy M. PRINCIOTTO
  • Patent number: 9499660
    Abstract: Compositions and methods using silicon-based cross-coupling agents in the formation of carbon-carbon and carbon-nitrogen bonds are described.
    Type: Grant
    Filed: June 7, 2013
    Date of Patent: November 22, 2016
    Assignee: The Trustees Of The University Of Pennsylvania
    Inventors: Adam T. Hoye, Won-suk Kim, Dionicio Martinez-Solorio, Amos B. Smith, III, Luis Sanchez, Rongbiao Tong, Minh Huu Nguyen, Bruno Melillo